MedTrace Logo

Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma

NCT01305122 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2021-02-09

No results posted yet for this study

Summary

This is a multicenter prospective study:2 independant cohorts of patients with OMS grade II glioma will be followed during 5 years.

* cohort A: patients in first-line treatment (surgery, radiotherapy or chemotherapy)
* cohort B: patients with disease simple monitoring.

The primary endpoint is to evaluate the impact of tumor and treatments on neurocognitive functions and quality of life, using validate and standard tests.

Conditions

  • OMS Grade II Glioma

Interventions

BEHAVIORAL

neurocognitive tests

* inclusion * 1 year * 3 years * 5 years

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Marie-Pierre SUNYACH, MD · Centre Léon Bérard, Lyon - FRANCE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2018-10-21
Completion
2018-10-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01305122 on ClinicalTrials.gov